Pharmaceutical Intermediate Neratinib 99% Purity Neratinib Powder Neratinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Neratinib
• Product Name: Neratinib
• Name: Neratinib Powder
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 698387-09-6
• Mf: C30h29cln6o3
• MW: 557.04
• Density: 1.337
• Melting Point: 756.97 C at 760 Mmhg
• Refractive Index: 10667
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

Pharmaceutical Intermediate Neratinib 99% Purity Neratinib Powder Neratinib

 

Product Description

Product Details

Product Name	Neratinib
Appearance	White to off-white powder
CAS No.	698387-09-6
MF	C30H29ClN6O3
MW	557.04

Neratinib is an irreversible epidermal grow factor receptor (EGFR) inhibitor.    It is a small molecule tyrosine kinase inhibitor targeting HER2 and HER1 after lapatinib.    It is an irreversible pan erbB receptor tyrosine kinase inhibitor.    It can selectively inhibit HER-1 and HER-2 (IC50 = 92 nmol / L and 59 nmol / L, respectively).    Clinical studies have shown that it has obvious therapeutic effect on non-small cell lung cancer, colon cancer and breast cancer.

Application & Function

Function:
1.  It  is a tyrosine kinase inhibitor.
2.  It has been used in extended adjuvant therapy for early HER2 positive breast cancer.
Application
The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal grow factor receptor complexes that are known to have central roles in cell proliferation and cancer.  Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM).  It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases.  As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefiti nib .  Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations.

Specification